Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not...









